Literature DB >> 1978887

Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid.

L Degos, C Chomienne, M T Daniel, R Berger, H Dombret, P Fenaux, S Castaigne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1978887     DOI： 10.1016/0140-6736(90)93135-c

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  16 in total

1.  All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells.

Authors:  C Chomienne; N Balitrand; P Ballerini; S Castaigne; H de Thé; L Degos
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 2.  Retinoic acid syndrome. Recognition, prevention and management.

Authors:  P Fenaux; S De Botton
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

3.  Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.

Authors:  M Ruthardt; U Testa; C Nervi; P F Ferrucci; F Grignani; E Puccetti; F Grignani; C Peschle; P G Pelicci
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

Review 4.  Clinical pharmacokinetics of tretinoin.

Authors:  M B Regazzi; I Iacona; C Gervasutti; M Lazzarino; S Toma
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

5.  Retinoic acid in the treatment of acute promyelocytic leukemia: inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events.

Authors:  V Runde; C Aul; T Südhoff; A Heyll; W Schneider
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

6.  Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Authors:  S Kayser; J Krzykalla; M A Elliott; K Norsworthy; P Gonzales; R K Hills; M R Baer; Z Ráčil; J Mayer; J Novak; P Žák; T Szotkowski; D Grimwade; N H Russell; R B Walter; E H Estey; J Westermann; M Görner; A Benner; A Krämer; B D Smith; A K Burnett; C Thiede; C Röllig; A D Ho; G Ehninger; R F Schlenk; M S Tallman; M J Levis; U Platzbecker
Journal:  Leukemia       Date:  2017-03-21       Impact factor: 11.528

7.  Direct effects of 13-cis and all-trans retinoic acid on normal bone marrow (BM) progenitors: comparative study on BM mononuclear cells and on isolated CD34+ BM cells.

Authors:  D R van Bockstaele; M Lenjou; H W Snoeck; F Lardon; P Stryckmans; M E Peetermans
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

8.  Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse.

Authors:  T Haferlach; H Löffler; B Glass; W Gassmann
Journal:  Clin Investig       Date:  1993-10

Review 9.  The molecular programme of tumour reversion: the steps beyond malignant transformation.

Authors:  Adam Telerman; Robert Amson
Journal:  Nat Rev Cancer       Date:  2009-01-30       Impact factor: 60.716

Review 10.  Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia.

Authors:  J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.